末期腎疾患（ESRD）市場規模、シェア、成長分析、治療別、診断別、最終用途別、地域別 - 産業予測、2025～2032年

末期腎疾患（ESRD）の世界市場規模は、2023年に1,120億8,000万米ドルと評価され、2024年の1,267億6,000万米ドルから2032年には3,393億8,000万米ドルに成長し、予測期間中（2025年～2032年）のCAGRは13.1％で成長する見通しです。

腎不全市場は、慢性腎臓病（CKD）の罹患率の上昇と、医療技術、特にメンテナンスの少ない透析システムや人工腎臓の進歩によって、大きな成長を遂げています。糖尿病、高血圧、生活習慣に起因するCKDは、世界人口の約10％が罹患しています。中国やインドのような開発途上国の高齢者層は特に脆弱で、末期腎疾患（ESRD）の症例は毎年5～7％増加しています。米国では、約8,000万人の成人がCKDのリスクを抱えており、CKDが主要な死亡原因であることが明らかになっています。市場の拡大には、ウェアラブル人工腎臓2.0のようなイノベーションと強固なヘルスケア・インフラが貢献しています。現在約7,500の透析クリニックのネットワークが拡大していることも、この拡大基調をさらに後押ししています。

目次

イントロダクション

• 調査の目的
• 調査範囲
• 定義

調査手法

• 情報調達
• 二次データと一次データの方法
• 市場規模予測
• 市場の前提条件と制限

エグゼクティブサマリー

• 世界市場の見通し
• 供給と需要の動向分析
• セグメント別機会分析

市場力学と見通し

• 市場概要
• 市場規模
• 市場力学
  • 促進要因と機会
  • 抑制要因と課題
• ポーターの分析

主な市場の考察

• 重要成功要因
• 競合の程度
• 主な投資機会
• 市場エコシステム
• 市場の魅力指数（2024年）
• PESTEL分析
• マクロ経済指標
• バリューチェーン分析
• 価格分析
• 製品パイプライン分析
• ケーススタディ分析
• 特許分析
• 規制分析

末期腎疾患（ESRD）市場規模：治療別

• 市場概要
• 移植
• 透析
  • 腹膜透析
  • 血液透析
  • ウェアラブル人工腎臓

末期腎疾患（ESRD）市場規模：診断別

• 市場概要
• 血液検査
• 尿検査
• 画像検査
• その他

末期腎疾患（ESRD）市場規模：最終用途別

• 市場概要
• 病院
• 透析センター
• その他

末期腎疾患（ESRD）市場規模

• 北米
  • 米国
  • カナダ
• 欧州
  • ドイツ
  • スペイン
  • フランス
  • 英国
  • イタリア
  • その他欧州地域
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• ラテンアメリカ
  • ブラジル
  • その他ラテンアメリカ地域
• 中東・アフリカ
  • GCC諸国
  • 南アフリカ
  • その他中東・アフリカ

競合情報

• 上位5社の比較
• 主要企業の市場ポジショニング（2024年）
• 主な市場企業が採用した戦略
• 市場の最近の動向
• 企業の市場シェア分析（2024年）
• 主要企業の企業プロファイル
  • 会社概要
  • 製品ポートフォリオ分析
  • セグメント別シェア分析
  • 収益の前年比比較（2022-2024）

主要企業プロファイル

• AngioDynamics, Inc.（US）
• Asahi Kasei Medical Co., Ltd.（Japan）
• B. Braun Melsungen AG（Germany）
• Baxter International, Inc.（US）
• Becton Dickinson and Company（US）
• Cantel Medical（US）
• DaVita Inc.（US）
• Fresenius Medical Care AG & Co. KGaA（Germany）
• JMS Co., Ltd.（Japan）
• Medtronic Plc（Ireland）
• Nikkiso Co., Ltd.（Japan）
• Nipro Corporation（Japan）
• Teleflex Incorporated（US）
• Toray Industries Inc.（Japan）
• U.S. Renal Care, Inc.（US）
• Pfizer Inc.（US）
• AstraZeneca（UK）
• Bristol-Myers Squibb Company（US）
• Dr. Reddy's Laboratories Ltd.（India）
• Endo International plc（Ireland）

結論と推奨事項

Global End-Stage Renal Disease (ESRD) Market size was valued at USD 112.08 billion in 2023 and is poised to grow from USD 126.76 billion in 2024 to USD 339.38 billion by 2032, growing at a CAGR of 13.1% during the forecast period (2025-2032).

The kidney failure market is experiencing significant growth, driven by the rising incidence of Chronic Kidney Disease (CKD) and advancements in medical technology, particularly low-maintenance dialysis systems and artificial kidneys. CKD, stemming from diabetes, hypertension, and lifestyle factors, affects roughly 10% of the global population. The elderly demographic in developing nations like China and India is particularly vulnerable, with cases of end-stage renal disease (ESRD) increasing annually by 5-7%. In the U.S., approximately 80 million adults are at risk for CKD, underscoring its status as a leading cause of mortality. Market expansion is fueled by innovations such as the Wearable Artificial Kidney 2.0 and a robust healthcare infrastructure. The growing network of dialysis clinics, now numbering around 7,500, further supports this upward trajectory.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global End-Stage Renal Disease (Esrd) market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global End-Stage Renal Disease (Esrd) Market Segmental Analysis

Global End-Stage Renal Disease (ESRD) Market is segmented by treatment, diagnosis, end use and region. Based on treatment, the market is segmented into transplant and dialysis. Based on diagnosis, the market is segmented into blood test, urine test, imaging test and others. Based on end use, the market is segmented into hospitals, dialysis centers and others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global End-Stage Renal Disease (Esrd) Market

One of the primary factors driving the global end-stage renal disease (ESRD) market is the rising incidence of chronic kidney disease (CKD), which is often linked to prevalent conditions like hypertension and diabetes. As these chronic ailments become increasingly common, a larger segment of the population is at risk of developing CKD, which can ultimately lead to ESRD. This growing patient demographic heightens the need for effective treatment modalities such as dialysis and kidney transplantation. Consequently, this heightened demand for specialized care and interventions is significantly contributing to the expansion and growth of the ESRD market on a global scale.

Restraints in the Global End-Stage Renal Disease (Esrd) Market

One significant challenge in the global End-Stage Renal Disease (ESRD) market is the restricted availability and accessibility of treatment options, particularly kidney transplantation. The demand for kidney transplants vastly overshadows the supply of compatible organs, resulting in extensive waiting lists and prolonged delays for patients in need. Furthermore, while dialysis serves as a viable treatment, it comes with its own set of obstacles, including issues related to patient adherence, high costs, and the requirement for frequent treatment sessions. These factors collectively hinder timely access to optimal care for individuals suffering from end-stage renal disease, ultimately affecting the growth of the market.

Market Trends of the Global End-Stage Renal Disease (Esrd) Market

A prominent market trend in the global end-stage renal disease (ESRD) sector is the rising prevalence of home-based dialysis treatments, which cater to patients' demands for convenience, reduced healthcare costs, and improved health outcomes. Growing preferences for modalities like peritoneal dialysis and home hemodialysis reflect a desire for increased flexibility and independence, allowing patients to undergo treatment in a familiar environment. This shift is further fueled by technological advancements, robust training initiatives, and supportive reimbursement frameworks, all of which facilitate the transition to home dialysis. Consequently, this trend is significantly propelling the growth and transformation of the ESRD market.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Product Pipeline Analysis
• Case Study Analysis
• Patent Analysis
• Regulatory Analysis

Global End-Stage Renal Disease (ESRD) Market Size by Treatment & CAGR (2025-2032)

• Market Overview
• Transplant
• Dialysis
  • Peritoneal Dialysis
  • Hemodialysis
  • Wearable Artificial Kidney

Global End-Stage Renal Disease (ESRD) Market Size by Diagnosis & CAGR (2025-2032)

• Market Overview
• Blood Test
• Urine Test
• Imaging Test
• Others

Global End-Stage Renal Disease (ESRD) Market Size by End Use & CAGR (2025-2032)

• Market Overview
• Hospitals
• Dialysis Centers
• Others

Global End-Stage Renal Disease (ESRD) Market Size & CAGR (2025-2032)

• North America (Treatment, Diagnosis, End Use)
  • US
  • Canada
• Europe (Treatment, Diagnosis, End Use)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Treatment, Diagnosis, End Use)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Treatment, Diagnosis, End Use)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Treatment, Diagnosis, End Use)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• AngioDynamics, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Asahi Kasei Medical Co., Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• B. Braun Melsungen AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Baxter International, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Becton Dickinson and Company (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cantel Medical (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• DaVita Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Fresenius Medical Care AG & Co. KGaA (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• JMS Co., Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Medtronic Plc (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Nikkiso Co., Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Nipro Corporation (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teleflex Incorporated (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Toray Industries Inc. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• U.S. Renal Care, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb Company (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dr. Reddy's Laboratories Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Endo International plc (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations